Observational studyBMC cancer2026
Comparison of perioperative chemotherapy and neoadjuvant chemoradiotherapy (CRT) in locally advanced resectable distal esophageal/esophagogastric junction (EGJ) adenocarcinomas.
Observational study in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the real-world outcomes of perioperative chemotherapy (ChT) and neoadjuvant chemoradiotherapy (CRT) in patients with locally advanced resectable distal esophageal and esophagogastric junction (EGJ) adenocarcinomas, with respect to pathological response, overall survival (OS), and recurrence-free survival (RFS). MATERIALS AND
methodsThis retrospective cohort study included 119 patients treated between 2016 and 2025 at a tertiary oncology center. Patients received either perioperative ChT (n = 68) or neoadjuvant CRT (n = 51) followed by curative-intent surgery. Baseline clinicopathological characteristics were comparable between groups. Survival outcomes were analyzed using the Kaplan-Meier method and compared with the log-rank test. Multivariable Cox proportional hazards regression models were constructed to identify independent prognostic factors for OS.
resultsA total of 119 patients were included, with comparable baseline characteristics between groups. Neoadjuvant CRT achieved higher pathological complete response and downstaging rates (p = 0.034 and p = 0.005), but no significant difference in overall survival (OS) (p = 0.944) or recurrence-free survival (RFS) (p = 0.449) was observed. In subgroup analyses, neoadjuvant CRT showed a trend toward improved OS in EGJ stage II (p = 0.078) and a significant RFS benefit in distal stage II (p = 0.014), whereas perioperative ChT demonstrated a significant OS advantage in EGJ stage III (p = 0.020). Treatment modality was not an independent predictor of OS, while nodal involvement was the strongest adverse prognostic factor.
conclusionNeoadjuvant CRT improved pathological response but did not provide a survival advantage over perioperative chemotherapy in the overall population. Subgroup analyses suggested stage- and location-dependent differences, although these findings are hypothesis-generating. Both strategies showed comparable survival outcomes, supporting individualized treatment selection. Larger prospective studies are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.